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Abstract: The absorption of drugs is limited by the epithelial barriers of the gastrointestinal tract.
One of the strategies to improve drug delivery is the modulation of barrier function by the targeted
opening of epithelial tight junctions. In our previous study the 18-mer amphiphilic PN159 peptide
was found to be an effective tight junction modulator on intestinal epithelial and blood–brain barrier
models. PN159, also known as KLAL or MAP, was described to interact with biological membranes
as a cell-penetrating peptide. In the present work we demonstrated that the PN159 peptide as
a penetration enhancer has a dual action on intestinal epithelial cells. The peptide safely and
reversibly enhanced the permeability of Caco-2 monolayers by opening the intercellular junctions.
The penetration of dextran molecules with different size and four efflux pump substrate drugs
was increased several folds. We identified claudin-4 and -7 junctional proteins by docking studies
as potential binding partners and targets of PN159 in the opening of the paracellular pathway.
In addition to the tight junction modulator action, the peptide showed cell membrane permeabilizing
and antimicrobial effects. This dual action is not general for cell-penetrating peptides (CPPs), since
the other three CPPs tested did not show barrier opening effects.
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1. Introduction
The oral administration of medicines is the most common method in drug therapy because of its
easy administration and good patient compliance. However, the absorption of several drugs is limited
in the gastrointestinal tract by the barriers composed of epithelial cell layers [1]. Since the non-invasive
delivery of orally administered hydrophilic drugs or biopharmaceuticals to the systemic circulation is
still a challenge, several strategies and molecules have been investigated as penetration enhancers,
including biosurfactants, sucrose esters and peptides [1–3].
Tight junctions (TJs) between epithelial cells form the anatomical basis of the intestinal barrier
which is one of the main biological barriers in our organism and the body’s largest interface with
the external environment [1]. These TJs, located in the apical regions of cells, close the intercellular
gap and thus determine the paracellular permeability and the tightness of the epithelial barriers [1,
4]. The absorption level and rate across biological barriers depends on the composition of cellular
membranes, the anatomical structures, and the expression pattern of TJ proteins and transporters in
the cell membrane [5]. TJs are complex structures composed of integral membrane proteins including
among others the occludin protein and the claudin family [6].
One of the basic strategies to improve drug delivery is the modulation of barrier function by
the targeted opening of TJs [1] Peptides which act directly on TJs and modulate their permeability
are potential candidates to increase the absorption of hydrophilic or large therapeutic molecules in a
non-invasive manner [1,7]. In our recent work six TJ modulator peptides acting on different targets
were compared using culture models of the intestinal and the blood-brain barriers [8]. All the six
peptides induced reversible opening of TJs but barrier selectivity and differences in efficacy were
observed. We found the PN159 as the most effective TJ modulator peptide on both barrier models [8].
This peptide was identified as a TJ modulator on cultured human bronchial epithelial cell layers
in 2005 [4]. PN159 peptide effectively increased the permeability of respiratory epithelium both in
culture and animal experiments [9]. The specific target proteins of the peptide were unknown, but
we demonstrated that PN159 interacts with the extracellular loops of integral membrane TJ proteins
claudin-1 and -5 [8].
The amino acid sequence of the 18-mer PN159, KLALKLALKALKAALKLA-amide, contains
several KLA motifs, and therefore it is also named as KLA or KLAL peptide [10]. The other name
of this peptide is MAP, which stands for model amphipathic peptide [11,12]. The structure of the
lipid vesicle-bound PN159 peptide is mostly α-helical [10] and strongly interacts with biological
membranes [10,13]. Cell-penetrating peptides (CPPs) are a group of short natural or synthetic peptides
with 5–30 amino acids, which by crossing cellular membranes can transport into cells a wide range
of small and macromolecules, including nucleic acids, proteins, imaging agents [14]. Based on their
physical-chemical properties, CPPs can be classified into groups. The most investigated CPPs belong to
the amphipathic class. These peptides contain hydrophilic and hydrophobic motifs and are especially
rich in lysine, arginine, leucine and alanine. Examples include the PN159 peptide [10,11]; the cyclic
ϕ-peptide [15] and Pep-1 [16]. Among the cationic CPPs penetratin [17] or polyarginine peptides [18]
are extensively investigated.
CPPs are structurally similar to antimicrobial peptides, which are important defense elements
of the innate immunity, and accordingly, they show an antimicrobial effect against pathogens [19].
Bacterial resistance is a growing clinical problem, as it was highlighted by the Infectious Diseases
Society of America publishing the list of ESKAPE pathogens (Enterobacter species, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterococcus faecium) [20].
This group of microbes causes the large majority of nosocomial infections throughout the world.
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The combat antibiotic resistance, CPPs can be promising alternative molecules, since increased
sensitivity (collateral sensitivity) for antimicrobial peptides were found in antibiotic-resistant
Escherichia coli strains [21].
As a culture model of the intestinal epithelial barrier, we used in our study the Caco-2 human cell
line resembling the epithelium of the small intestine both from structural and functional aspects [22].
The cells have polarized cell morphology, grow in monolayer, possess microvilli, form TJs, express
nutrient and efflux transporters, and show good correlation with in vivo data [23,24]. Caco-2 epithelial
cells are routinely used in drug permeability studies [24,25].
Crucial parameters for absorption enhancers include their safety, reversibility and efficacy.
There are no data available about the effectiveness and safety of PN159 peptide on the intestinal
barrier, so our primary goal was to test the TJ modulator peptide for these aspects. Therefore, the aim
of the study was to (i) determine the influence of long-time and concentration-dependent effects of
treatments with PN159 peptide on intestinal epithelial cell viability, barrier function and recovery; (ii)
test the effect of PN159 peptide on drug penetration across the intestinal barrier model; (iii) identify
further potential targets of this TJ modulator peptide by molecular modelling; (iv) measure the cell
uptake of the PN159 in intestinal epithelial cells and its antimicrobial activity on ESKAPE pathogens;
and (iv) test other CPPs for the TJ modulator effect.
2. Materials and Methods
2.1. Materials
All reagents were purchased from Sigma-Aldrich Ltd. (Budapest, Hungary) except for those
specifically mentioned.
2.2. Peptide Synthesis
PN159 peptide (KLALKLALKALKAALKLA-amide) [4,10], and Pep-1 (Chariot) peptide
(KETWWETWWTEWSQPKKKRKV-amide) were synthesized manually on a 0.5 mmolar scale with
the use of standard Fmoc-chemistry on a Rink-amide resin. Couplings were performed in DMF with
three-fold excess of DCC, HOBt, and Fmoc-amino acids for 3 h at ambient temperature. In the case of
octaarginine (RRRRRRRR-amide, R8) three-fold excess of HATU and six-fold excess of DIPEA was used.
Fmoc deprotection was performed in 20% piperidine/DMF mixture for 20 min. The peptides were
cleaved from the resin by incubating them with the mixture of TFA/water/triisopropylsilane (48:1:1
volume ratio), precipitated with diethyl-ether and lyophilized. Crude peptides were purified using a
Shimadzu semi-preparative high-performance liquid chromatography (HPLC) instrument equipped
with a Phenomenex JupiterC18 column, in the following solvent system: (A) 0.1% aqueous TFA and
(B) 0.1% TFA in 80% aqueous acetonitrile, in a linear gradient mode. Analysis and purity control were
carried out on an analytical HPLC instrument (HP Model 1100 liquid chromatograph equipped with
a Phenomenex Jupiter C18 column). Quality control of the peptides was done by performing mass
spectrometric measurements on a FinniganTSQ-7000 triple quadrupole mass spectrometer in positive
ion mode.
The cyclic ϕ-peptide (cyclo[CGGFWRRRRGE(εAca)G])was also synthesized manually on a
0.5 mmolar scale with the use of Boc-chemistry on a MBHA-HCl resin, by applying a native chemical
ligation strategy. Couplings were performed in DMF with three-fold excess of DIC, HOBt, and
Boc-amino acids for 3 h at ambient temperature. Boc deprotection was performed in TFA/DCM (1:1
volume ratio) mixture for 20 min. The peptide was cleaved from the resin by the standard HF method.
Native chemical ligation was performed with 2% thiophenol in an ammoniumacetate solution (0.1 M)
at room temperature for 12h. Cyclic crude peptide was purified and analyzed as described above.
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2.3. Cell Culture
The human Caco-2 intestinal epithelial cell line was purchased from ATCC (cat.no. HTB-37).
Caco-2 cells were grown in DMEM/HAM’s F-12 culture medium with stable glutamine
(Life Technologies, Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(Life Technologies, Gibco, Carlsbad, CA, USA and 50 µg/mL gentamycin in a humidified incubator
with 5% CO2 at 37 ◦C. All plastic surfaces were coated with 0.05% rat tail collagen in sterile distilled
water before cell seeding.
2.4. Peptide Treatment
The PN159 peptide stock solution (5 mM) was prepared freshly in sterile DMSO. Treatment
solutions were further diluted in Ringer-Hepes (150 mM NaCl, 6 mM NaHCO3, 5.2 mM KCl,
2.2 mM CaCl2, 0.2 mM MgCl2, 2.8 mM D-glucose, 5 mM Hepes; pH 7.4) or cell culture medium.
Final concentrations of the peptide in treatment solutions were as follows: 1, 3, 10, 30 and 100
µM for cell viability assays; 1, 3, 10 and 30 µM for the barrier integrity assays and 10 µM for the
recovery measurements.
The stock solutions of the three reference CPPs were the following: Pep-1: 1 mM in distilled water
(DW); R8: 1 mM in DW; ϕ-peptide, 5 mM in DW and 2.5% DMSO. The 100 µM working solutions
were dissolved in cell culture medium or Ringer–Hepes buffer. We prepared all solutions freshly in
sterile conditions.
2.5. MTT Assay
For the cell viability assays Caco-2 epithelial cells were seeded to 96-well plates at the density of
6 × 103 cells/well (Orange Scientific) and cultured for 3-5 days. Confluent cultures were treated with
PN159 peptide (1, 3, 10, 30 and 100 µM) in phenol red free DMEM (Life Technologies, Gibco, Carlsbad,
CA, USA) for 1-h. This viability assay was performed at three different time points: (i) immediately
after the 1-h treatment, (ii) at one-day recovery, (iii) at one-week recovery. To determine 100% toxicity,
cells were incubated with 1 mg/mL Triton X-100 detergent. After treatment the medium was changed
and 0.5 mg/mL MTT (3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution was
added to the cells for 3 h. During the incubation cells were kept in a CO2 incubator. The metabolic
activity of cells is reflected by the conversion of the yellow MTT dye to purple formazan. Formazan
crystals were dissolved in DMSO and the amount of converted dye was determined by measuring
absorbance at 595 nm wavelength with a microplate reader (Fluostar Optima, BMG Labtechnologies,
Ortenberg, Germany). Cell viability and/or metabolic activity was calculated as percentage of dye
conversion by non-treated cells.
2.6. Impedance Measurement
Kinetics of epithelial cell reaction to PN159 peptide treatment was monitored by impedance
measurement at 10 kHz (RTCA-SP instrument, ACEA Biosciences, San Diego, CA, USA). Impedance
measurement is non-invasive, label-free and real time, and linearly correlates with adherence, growth,
number and viability of cells [2,26]. For background measurements 50 µL cell culture medium was
added to the wells, then cells were seeded at a density of 6 × 103 cells/well to the coated 96-well
plates with integrated gold electrodes (E-plate 96, ACEA Biosciences). Cells were cultured for 5–7 days
in a CO2 incubator at 37 ◦C and monitored every 10 min until the end of experiments. Cells were
treated with PN159 peptide solutions at 1, 3, 10, 30 and 100 µM concentrations at the beginning of
the plateau phase of growth and the effects were followed for 1-h or 24 h. To measure cell recovery,
peptide solutions were changed to culture medium and the impedance was monitored for one week.
Culture medium was changed every 2 days. Caco-2 cells were also treated with the three selected CPPs,
Pep-1, R8 and ϕ-peptide, at 100 µM concentrations at the beginning of the plateau phase of cell growth
for 24-h. Triton X-100 detergent (1 mg/mL) was used as a reference compound to induce cell death.
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Cell index was defined as Rn-Rb at each time point of measurement, where Rn is the cell-electrode
impedance of the well when it contains cells and Rb is the background impedance of the well with the
medium alone.
2.7. Measurement of the Electrical Resistance of Caco-2 Cell Layers
For the measurement of barrier integrity Caco-2 cells were seeded onto culture inserts (Transwell
3460, polyester membrane, 0.4 µm pore size, Corning Costar) and cultured for three weeks [2,24].
Transepithelial electrical resistance (TEER) reflects the tightness of the intercellular junctions. TEER was
measured by an EVOM volt-ohmmeter (World Precision Instruments, Sarasota, FL, USA) combined
with STX-2 electrodes, and was expressed relative to the surface area of the monolayers (Ω × cm2).
Resistance of cell-free inserts (130 Ω × cm2) was subtracted from the measured values. TEER
values were measured before and right after permeability experiments). TEER values indicated
the integrity and paracellular permeability of cell layers for ions. The TEER of Caco-2 monolayers was
1302 ± 49 Ω × cm2 (mean ± SD; n = 46) after 3 weeks culturing. For the recovery experiment, after
changing the 10 µM peptide solutions to culture medium, TEER was monitored for one day.
2.8. Penetration of Marker and Drug Molecules across Caco-2 Cell Layers
In the permeability experiments inserts with Caco-2 cell layers grown for 3 weeks were transferred
to 12-well plates containing 1.5 mL Ringer–Hepes buffer in the lower (basal or acceptor) compartments.
In the upper or apical compartments culture medium was replaced by 0.5 mL buffer containing
peptide solutions: PN159 peptide at 1, 3, 10 and 30 µM concentrations and CPPs at 100 µM
concentration. Permeability marker molecules albumin (1 mg/mL; Mw: 65 kDa) labeled with Evans
blue (167.5 µg/mL) and fluorescein (10 µg/mL; Mw: 376 Da) were added 30 min later. The incubation
with permeability markers in the presence of PN159 peptide lasted for 30 min. In case of CPPs
the incubation time with fluorescein was 1-h. Samples were collected from both compartments
and the concentrations of the marker molecules were determined by a fluorescence multi-well plate
reader (Fluostar Optima; excitation wavelength: 485 nm, emission wavelength: 535 nm in the case of
fluorescein and excitation wavelength: 584 nm, emission wavelength: 680 nm in the case of Evans-blue
labeled albumin). Fluorescein isothiocyanate (FITC)-labelled dextran marker molecules (Table 1) were
used at 1 mM concentrations, and fluorescence intensities of collected samples were measured using
a Fluorolog FL3-22 (Horiba Jobin Yvon, Paris, France) spectrofluorometer using 492 nm excitation
wavelength, 515 nm emission wavelength, and 0.5 s integration time. Drugs were used at 10 µM
concentrations and samples were measured by HPLC as described below. The apparent permeability
coefficients (Papp) were calculated as described previously [8,24]. Briefly, cleared volume was calculated
from the concentration difference of the tracer in the basal compartments (∆[C]B) after 30 min and
apical compartments at 0 h ([C]A), the volume of the basal compartment (VB; 1.5 mL) and the surface
area available for permeability (A; 1.1 cm2).
Table 1. The amino acid sequences of the tested cell-penetrating peptides.
CPPs Amino Acid Sequence References
PN159 (KLAL/MAP) KLALKLALKALKAALKLA-amide [4,10]
Pep-1 KETWWETWWTEWSQPKKKRKV-amide [16]
R8 RRRRRRRR-amide [18]
ϕ-peptide cyclo[CGGFWRRRRGE(εAca)G] [15]
2.9. High-Performance Liquid Chromatography (HPLC)Analytical Procedures
Analytical measurements were performed on a Merck-Hitachi LaChrom HPLC system equipped
with an ultraviolet (UV) and fluorescence detector (Merck, Darmstadt, Germany). All reagents used
were of analytical reagent grade. Atenolol and verapamil were determined by using a Gemini C18
column (150 × 3 mm, 5 µm, 110 Å; Phenomenex Inc., Torrance, CA, USA) operated at 0.5 mL/min
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flow rate, maintained at 35◦C. For atenolol measurements isocratic elution was applied with a mixture
of 300 mL methanol, 400 mL 100 mM ammonium acetate, 20 mL 10% ammonium-hydroxide and 2 mL
0.1 M ethylenediaminetetraacetic acid. The mobile phase for verapamil consisted of 350 mL methanol
with 250 mL 20 mM ammonium acetate and 2 mL 10% trifluoroacetic acid with isocratic elution,
at 0.5 mL/min flow rate. UV detection for atenolol was performed at 270 nm while for verapamil
the 230 nm wavelength was adjusted. The calibration curve was linear (r2 = 0.9999) over a range of
0.01–1.5 µM for atenolol. The calibration curve for verapamil also showed a good linearity within the
examined concentration range of 0.01–1 µM (r2 = 0.9952). In both cases 10µL sample was injected into
the chromatographic system. Samples at higher than 1 µM atenolol and verapamil concentrations
were 10× diluted with Ringer–Hepes solution.
HPLC measurement of quinidine was performed using a YMC Pack Pro C18 column
(RS 150 × 2.1 mm, 5 µm, 80 Å; YMC America Inc., Allentown, PA, USA) equipped with a guard
column operated at 0.2 mL/min flow rate. The chromatographic column was maintained at 40 ◦C
and the 5 µL sample was injected onto the column. The elution of quinidine was performed with
a buffer containing a mixture of 100 mL methanol, 250 mL 0.1% ammonium acetate, and 4 mL
10% trifluoroacetic acid. Quinidine was quantified at 250/430 nm excitation/emission wavelengths.
The calibration curve was linear over the quantitation range of 0.01–1 µM (r2 = 0.9984).
HPLC measurement of cimetidine was performed using a Gemini NX column (150 × 4.6 mm,
3 µM) equipped with a guard column operated at 0.8 mL/min flow rate. The column temperature
was maintained at 40 ◦C and a 20 µL sample was injected onto the chromatographic system. A buffer
comprising of 15% acetonitrile and 85% 100 mM ammonium acetate was utilized for the isocratic
elution of cimetidine. UV detection was set at 228 nm. The calibration curve was linear (r2 = 0.9999)
over the range of 0.01–10 µM.
2.10. Electron Microscopy
Cells grown on culture inserts were treated with 10 µM PN159 peptide for 30 min and
fixed immediately after treatment or after a 1-day recovery. Cells were briefly washed with
phosphate-buffered saline (PBS) and fixed with 3% paraformaldehyde containing 0.5% glutaraldehyde
in cacodylate buffer (pH 7.4) for 30 min at 4 ◦C. After washing with the buffer several times, cells were
postfixed in 1% OsO4 for 20 min. Following a rinse with distilled water, the cells were block stained
with 1% uranyl acetate in 50% ethanol for 20 min, dehydrated in graded ethanol and after the last step
of dehydration inserts were placed in the 1:1 mixture of ethanol and Taab 812 (Taab; Aldermaston,
Berks, UK) for 10 min at 30◦C. Finally, the membranes of the culture inserts with the cells were removed
from their support and embedded in Taab 812. Polymerization was performed overnight at 60◦C.
Ultrathin sections were cut perpendicularly for the membrane using a Leica EM UC6 ultramicrotome
(Nussloch, Germany) and picked up on formvar-coated single-slot copper grids. The sections were
examined using a Hitachi 7100 transmission electron microscope (Hitachi Ltd., Tokyo, Japan) and a
side-mounted Veleta CCD camera (Olympus Soft Imaging Solutions). Altogether, 105 non-overlapping
images from the 3 groups at the same magnification were analyzed for the presence or absence of tight
junctions (control group n = 28; PN159 group n = 42; recovery group n = 35).
2.11. Immunohistochemistry
Morphological changes in interepithelial junctions after treatment with different concentrations
of CPPs (100 µM) and PN159 peptide (1, 3, 10, 30 and 100 µM) were followed by immunostaining
for claudin-1 integral membrane tight junction protein, β-catenin and zonula occludens protein-1
(ZO-1) cytoplasmic linker proteins. F-actin was stained by fluorescently labeled phalloidin. Treatments
lasted for 1 h. After peptide treatment cell layers were washed with PBS and fixed with a 1:1 mixture
of ice cold acetone and methanol for 2 min. Cells were blocked with 3% bovine serum albumin in
PBS and incubated with primary antibodies mouse anti-claudin-1 and -4, rabbit anti-ZO-1 and rabbit
anti-β-catenin (Life Technologies, Carlsbad, CA, USA) overnight. Fluorescent Atto 647N-phalloidin
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(ATTO-TEC GmbH, Germany) lasted for 1 h. Incubation with Alexa Fluor-488-labeled anti-mouse and
anti-rabbit secondary antibodies (Life Technologies, Invitrogen, USA) lasted for 1 h. Bis-benzimide
dye (Hoechst 33342) was used to stain cell nuclei. After mounting (Fluoromount-G; Southern Biotech,
Birmingham, AL, USA) the samples staining was visualized by a Leica TCS SP5 confocal laser scanning
microscope (Leica Microsystems GmbH, Wetzlar, Germany) and Visitron spinning disk confocal system
(Visitron Systems GmbH, Puchheim, Germany).
2.12. Circular Dichroism (CD) Spectroscopy
Far-UV circular dichroism (CD) spectra of the peptides were recorded at 25◦C temperature on a
J-810 spectropolarimeter (JASCO International Co. Ltd., Tokyo, Japan). The CD spectra were measured
between 260 nm and 185 nm with an optical pathlength of 1 mm, at a peptide concentration of
0.1 mg/mL in Milli-Q water diluted directly from powder. The bandwidth was 2 nm and data pitch
0.5 nm, the scan speed was set to 100 nm/min and the integration time was 1 sec. Ten spectra were
accumulated and plotted. The data were analyzed by CDSSTR method [27]. To test the thermostability
of the peptide structure the CD spectra were recorded between 25 ◦C and 55 ◦C temperature with a
ramp rate of 5 ◦C/min on a JASCO J-810 spectropolarimeter by using a Peltier sample holder. The CD
spectra were measured immediately between 260 and 185 nm with an optical pathlength of 1 mm,
the peptide concentration was 0.1 mg/mL in Milli-Q water. The bandwidth was 2 nm and data pitch
1 nm, the scan speed was set to 100 nm/min, and the integration time was 1 sec. Five spectra were
accumulated and plotted.
2.13. Molecular Modelling
Protein structures were obtained by homology modeling using the MODELLER program
package [28]. First, the structure of mouse claudin-15 was completed by homology modelling because
its X-ray structure file is lacking the fragment of residues from 34 to 41 [29]. Human claudins 1, 4 and 7
were homology modeled using the completed mouse claudin-15 as a template. The protein homology
models were further relaxed by a short (400 ns) molecular dynamics simulation in which the proteins
were embedded in a 95 by 95 Å POPC bilayer-water system containing 150 mM NaCl. Molecular
dynamics simulations were performed by the program NAMD [30], using the CHARMM27 molecular
force field with CMAP correction. The results were visualized by VMD v1.9.1. [31]. The docking studies
were performed by the CABS docking server [32] and the resulting C-alpha traces were reconstructed
by MODELLER using the python script supplied by the server homepage.
2.14. Visualization of the Uptake of PN159 Peptide in Caco-2 Cells
The Caco-2 cells were grown on glass bottomed petri dishes coated with collagen to visualize the
cellular uptake of the Bodipy FL maleimide labeled (BODIPY FL N-(2-aminoethyl) maleimide, Thermo
Fischer, Waltham, MA, USA) PN159 peptide. The cells were treated with peptide at concentrations
of 1, 3 and 10 µM for 5 min. To stain the cell nuclei the H33342dye (1 µg/mL) was used before
peptide treatment for 10 min. After peptide incubation the living cells were washed three times with
Ringer–Hepes buffer supplemented with 1%fetal bovine serum (FBS) and examined immediately with
a Visitron spinning disk confocal system.
In the case of the co-localization analysis the labeled PN159 peptide was used in 10 µM for 5 min.
Then the cellular uptake cells were fixed and immunohistochemistry was performed for claudin-4.
The samples were mounted and visualized by a Leica TCS SP5 confocal laser-scanning microscope.
2.15. Determination of Minimum Inhibitory Concentration (MIC) on Microbial Pathogens
We tested the spectrum of activity of PN159 on a set of five sensitive ESKAPE pathogens:
Staphylococcus aureus (ATCC 29213), Klebsiella pneumoniae (ATCC 10031), Acinetobacter baumannii (ATCC
17978), Pseudomonas aeruginosa (ATCC 27853), Enterobacter cloacae spp. cloacae (ATCC 13047); and one
vancomycin resistant ESKAPE pathogen, Enterococcus faecium (ATCC 700221). The MIC of PN159 on the
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6 sensitive and resistant ESKAPE pathogenic strains was determined in cation-adjusted Muller–Hinton
broth. For Enterococcus faecium, which does not grow in Muller-Hinton broth, Brain-Heart-Infusion
broth was used. Minimum inhibitory concentrations (MICs) were determined by using a standard
serial broth dilution technique [33]. Briefly, 11-step serial dilutions were prepared in 96-well microtiter
plates with three biological replicates per strain. Pathogens were inoculated into each well at a
density of 5×105 bacteria/mL, and the plates were incubated at 37 ◦C. Plates were shaken at 300 rpm
during incubation for 18 h. Cell growth was monitored by measuring the optical density (OD600
value, Synergy 2 microplate reader BioTek Instruments Inc, Winooski, VT, USA). MIC was defined as
complete growth inhibition (i.e., OD600 < 0.05). As reference compounds we tested the antimicrobial
activity of three bactericidal drugs with different modes of action. Cefoxitin inhibits the cell wall
synthesis, gentamicin (Applichem GmbH, Darmstadt, Germany) is a 30S ribosomal subunit inhibitor,
while ciprofloxacin is a gyrase inhibitor. The highest tested concentrations were 100 µg/mL in the case
of cefoxitin and gentamicin, and 10 µg/mL for ciprofloxacin.
2.16. Statistical Analysis
For statistical analysis Graph Pad Prism 5.0 software (Graph Pad Software Inc., San Diego,
CA, USA) was used. All data presented are means ± SD. Values were compared using analysis of
variance followed by Dunnett’s test. Changes were considered statistically significant at p < 0.05.
All measurements were repeated three times and the number of parallel samples was minimum three.
3. Results
3.1. Concentration-Dependent Effect of PN159 Peptide on Epithelial Cell Viability
The colorimetric endpoint MTT test was performed after a 1-h treatment with different PN159
peptide concentrations at three different time points: (i) immediately after the 1-h treatment, (ii) at
one-day recovery and (iii) at one-week recovery (Figure 1A). Low concentrations of the peptide
(1–10 µM) did not decrease cell viability, while cell damage was found at higher, 30 and 100 µM
concentrations. The cytotoxic effect of PN159 at 100 µM concentration was not reversible after one day
or even one week. The kinetics of PN159 effects on Caco-2 cells were followed by real-time impedance
measurements after 1-h (Figure 1B) or one-day treatment (Figure 1C). In both conditions only the two
highest peptide concentrations decreased the cell impedance indicating cell damage, similarly to the
results of the MTT assay.
Based on both tests, PN159 peptide treatment for 1-h was non-toxic at 10 µM or lower
concentrations, reversible at 30 µM and toxic at the highest 100 µM concentration. The results obtained
by MTT test and impedance measurement on Caco-2 cells were similar (Figure 1) and indicated that
all the used concentrations of PN159 peptide were safe, except the 100 µM. Because of its toxicity, the
100 µM concentration was not used in further experiments.
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Figure 1. (A) MTT assay after 1-h treatment with PN159 peptide on Caco-2 cells followed by 1-h, 1-day or 
1-week recovery. The MTT values are given as percent of the control group (100% viability). Values are 
presented as means ± SD, n = 3–8. Statistical analysis: analysis of variance (ANOVA) followed by Dunnett 
test, p < 0.05 as compared with the control groups. (B) Impedance measurements after 1-h treatment and 
(C) 1-day treatment followed by a recovery phase of 1-week. The effects of PN159 peptide on the impedance 
were shown as normalized cell index. Values are presented as means ± SD, n = 3–8. 
Fig re . ( ) t ent ith PN159 peptide on Caco-2 cells followed by 1-h, 1-day
or 1-week recovery. The MTT values are given as percent of the ( 00 viability). Values
a presented as means ± SD, n = 3–8. St tistical analysis: analysis of variance ( NOVA) followed
by Dunnett test, p < 0.05 as compared with the control groups. (B) Impedance measurements after
1-h tre tment and (C) 1-day treatment followed by a recovery phase of 1-week. The effects of PN159
p ptide on the impedance w re shown as normalized cell index. Values are presented as means ± SD,
n = 3–8.
3.2. Concentration-Dependent Effect of PN159 Peptide on Intestinal Epithelial Barrier Integrity
All tested concentrations of the PN159 peptide significantly decreased the resistance of epithelial
cell layers after a 1-h treatment (Figure 2A). The two highest concentrations, 10 and 30 µM, opened the
paracellular barrier the most, causing 80–90% decrease in TEER. In concordance, these two highest
concentrations of PN159 showed the most effective permeability enhancer activity for both fluorescein
and albumin (Figure 2B). Because the peptide was safe for the cells but effectively opened the barrier
at 10 µM, this concentration was selected to reveal the kinetics of the reversibility of barrier opening,
and to investigate its effects on drug penetration.
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3.3. Reversible Effect of PN159 Peptide on the Opening of the Paracellular Cleft
The effect of PN159 peptide was very rapid, the electrical resistance dropped already to 42% of the
control value after 1-min treatment (Figure 3A). The decrease of TEER continued until the end of the
30-min treatment (5 min: 16%, 15 min: 2.7%, 30 min: 1.4% of the control value). After the removal of the
peptide the barrier function of Caco-2 cells was restored about 44% of the control value at six hours and
a complete recovery could be observed at the 20 h timepoint. Intact TJs providing the morphological
basis of barrier functions were visualized between Caco-2 epithelial cells in the control group by
transmission electron microscopy, but no junctions were observed following treatment with PN159
peptide (Figure 3B). The disappearance of intercellular TJs was reversible, because after 1-day recovery
the ultrastructure of epithelial junctions became similar to control cells. No open TJs were observed in
the control or recovery groups by checking the electron micrographs (28–42 images/groups).Pharmaceutics 2019, 11, x FOR PEER REVIEW 10 of 21 
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control conditions the permeability of atenolol and cimetidine was the lowest from the tested 
molecules, while the highest penetration was measured for quinidine and verapamil on Caco-2 cells. 
PN159 treatment caused more than 30-fold change for atenolol and cimetidine which penetrate 
slowly across the cells layers. The peptide increased about 2 fold the permeability of the intestinal 
culture model for the lipophilic quinidine and verapamil, which already showed a good penetration. 
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Reversible effect of PN159 peptide (10 µM, 30-min treatment, 24-h recovery) on Caco-2
cells. (A) Kinetic analysis of transepithelial electrical resistance (TEER) after PN159 pepti e treat ent.
(B) Transmission electron micrographs of cell–cell connections (arrowheads); bar = 400 nm.
3.4. Effects of PN159 Peptide on the Penetration of Dextran Marker Molecules and Drugs
All these previous functional and morphological results pointed to the TJ opening effect of PN159
in Caco-2 cells which potentially can be exploited to increase drug penetration across the intestinal
barrier. The permeability of Caco-2 monolayers was measured in the apical to basal (intestine to
blood) direction for four water-soluble dextran marker molecules of different sizes (4–40 kDa) and four
drugs, the hydrophilic atenolol and cimetidine, and the lipophilic quinidine and verapamil (Table 2).
All four drugs are substrates of active efflux transporters [24]. The apparent permeability coefficients
of the large fluorescein isothiocyanate-labeled dextran (FD) macromolecules were very low in control
conditions but they were elevated by 159-400 fold following PN159 treatment. The highest increase
was measured in the case of FD-40, the largest macromolecule. In control conditions the permeability
of atenolol and cimetidine was the lowest from the tested molecules, while the highest penetration
was measured for quinidine and verapamil on Caco-2 cells. PN159 treatment caused more than
30-fold change for atenolol and cimetidine which penetrate slowly across the cells layers. The peptide
increased about 2 fold the permeability of the intestinal culture model for the lipophilic quinidine and
verapamil, which already showed a good penetration.
Pharmaceutics 2019, 11, 73 11 of 21
Table 2. Apparent permeability coefficients of dextran marker molecules and drugs in the apical-basal
direction (Papp A-B, 10−6 cm/s) in control and PN159 treated cultures. The differences between control
and treated groups were expressed in fold changes. FD, fluorescein isothiocyanate-labeled dextran.
Markers and Drug Control PN159 Fold Change
FD-4 0.021 ± 0.001 4.2 ± 0.1 200.0
FD-10 0.025 ± 0.010 4.8 ± 0.7 192.0
FD-20 0.022 ± 0.002 3.5 ± 1.0 159.0
FD-40 0.015 ± 0.003 6.0 ± 0.3 400.0
atenolol 1.2 ± 0.3 36.3 ± 1.9 30.0
cimetidine 0.9 ± 0.2 34.5 ± 4.5 38.3
quinidine 45.0 ± 13.3 72.6 ± 2.4 1.6
verapamil 46.2 ± 3.9 86.7 ± 18.8 1.9
3.5. The Effect of PN159 Peptide on the Staining of Junctional Proteins and F-Actin
The concentration-dependent effects of the peptide on epithelial barrier integrity in Caco-2 cells
were confirmed by the immunostaining of junctional proteins claudin-1, ZO-1 and β-catenin, and the
labeling of the actin cytoskeleton (F-actin) (Figure 4). The 1 µM concentration of the peptide caused a
slight effect on cell morphology. At higher than 3 µM concentrations significant changes were observed
both in the junctional protein pattern and in the actin cytoskeleton organization. Claudin-1 was the
junctional protein most sensitive to the peptide treatment. PN159 at a concentration of 10 µM caused a
drastic change in actin cytoskeleton and epithelial junctional morphology, with a visible opening of
intercellular junctions.
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3.6. Molecular Modeling of Human Claudin Proteins and Docking of PN159 Peptide 
According to the CD spectra obtained, the secondary structure of PN159 peptide contains 11% 
α-helix, 31% β-sheet, 24% turns and 34% unordered structure (Figure 5A). This secondary structure 
of PN159 peptide was stable between 25 and 55 °C (Figure 5B). In concordance with the result of CD 
spectra, similar secondary structure motifs were found by molecular modeling (Figure 5C). 
Figure 4. Effects of P 159 peptide on junctional orphology of Caco-2 cells. I unostaining for
claudin-1, β-catenin and zonula occludens-1 (ZO-1) junctional proteins and fluorescent staining for
F-actin are shown in control conditions or after 1-hour peptide treat ent. Green color: i unostaining
for ZO-1, β-catenin and claudin-1. Blue color: staining of cell nuclei. Red color staining of F-actin.
Bar = 20 µm. Arrowheads indicate the opened junctions between the cells.
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3.6. Molecular Modeling of Human Claudin Proteins and Docking of PN159 Peptide
According to the CD spectra obtained, the secondary structure of PN159 peptide contains 11%
α-helix, 31% β-sheet, 24% turns and 34% unordered structure (Figure 5A). This secondary structure
of PN159 peptide was stable between 25 and 55 ◦C (Figure 5B). In concordance with the result of CD
spectra, similar secondary structure motifs were found by molecular modeling (Figure 5C).Pharmaceutics 2019, 11, x FOR PEER REVIEW 12 of 21 
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claudin-1, -3, -4, and -7 monomers, highly expressed in Caco-2 cells [34] was performed on the CABS 
server (Figure 6B). Favorable docking poses located around extracellular loops ECL1 and ECL2 were 
sought by both energetic and geometric considerations and analyzed in all docking trajectories. 
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for the total energies, but as low as possible for all energy components simultaneously. Thus, the 
“ligand energy”, “interaction energy” and “total energy” values were investigated. Based on the 
modeling, energetically highly favorable interactions were found between PN159 and the ECLs of 
claudin-1, -4 and -7, but not for claudin-3 (Table 3). Docked poses of PN159 with ECLs of claudin-1, 
-4 and -7 are shown on Figure 6B. 
Table 3. Docking energy components of PN159 to selected human claudin monomers. Etot, total 
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Eint −63 −59 −79 −186 
Etot −1228 −1163 −1229 −1798 
The amino acid sequence of ECL1 and ECL2 of the three claudins which showed interaction with 
the TJ modulator peptide were compared and the most important amino acids which interact with 
PN159 were identified (Figure 6C). Four residues in ECL1, the polar Q44 and S/N/D53, the 
hydrophobic V55 and L71, and in ECL2 the polar N/Q156 participate in major interactions with the 
peptide. Q44 and V55 residues of claudin-1 and -7 form a binding pocket for L11 of the peptide, and 
the same two residues of claudin-4 bind L6 and K9 (Figure 6C). The polar S/N/D53 and L71 of claudin-
4 and -7 interact with K5, while the same amino acids of claudin-1 bind K12. The N/Q156 amino acid 
of ECL2 of all three claudins interacts with lysine: in the case of claudin-1 this is L17 of PN159, for 
claudin-4 L2, and for claudin-7 L6, L8, L15, L17. Based on the docking results, lysine, especially K1 
and K5 and leucine L6 and L17 of PN159 interact with all three claudins examined (Figure 6D). After 
docking of the peptide disappearance of β-strands in ECLs of claudins was observed (Figure 6B), 
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Claudin protein structures were obtained by homology modeling using the MODELLER program
package (Figure 6A). Docking of PN159 peptide to full length homology modeled human claudin-1,
-3, -4, and -7 monomers, highly expressed in Caco-2 cells [34] was performed on the CABS server
(Figure 6B). Favorable docking poses located around extracellular loops ECL1 and ECL2 were sought
by both energetic and geometric considerations and analyzed in all docking trajectories. Docking
energies (“total energy”) were decomposed to “ligand energy”, “interaction energy” and “receptor
energy” parts (Table 3). Correct docking poses were expected to have low values not only for the total
energies, but as low as possible for all energy components simultaneously. Thus, the “ligand energy”,
“interaction energy” and “total energy” values were investigated. Based on the modeling, energetically
highly favorable interactions were found between PN159 and the ECLs of claudin-1, -4 and -7, but
not for claudin-3 (Table 3). Docked poses of PN159 with ECLs of claudin-1, -4 and -7 are shown on
Figure 6B.
Table 3. Docking energy components of PN159 to selected human claudin monomers. Etot, total energy;
Elig, ligand energy; Eint, interaction energy.
Energy Claudin-1 laudin-3 Claudin-4 Claudin-7
Elig −34 17 −61 −32
Eint −63 59 −79 −186
Etot −12 8 163 −1229 −1798
The amino acid sequence of ECL1 and ECL2 of the three claudins which showed interaction
with the TJ modulator peptide were compared and the most important amino acids which interact
with PN159 were identified (Figure 6C). Four residues in ECL1, the polar Q44 and S/N/D53, the
Pharmaceutics 2019, 11, 73 13 of 21
hydrophobic V55 and L71, and in ECL2 the polar N/Q156 participate in major interactions with the
peptide. Q44 and V55 residues of claudin-1 and -7 form a binding pocket for L11 of the peptide, and the
same two residues of claudin-4 bind L6 and K9 (Figure 6C). The polar S/N/D53 and L71 of claudin-4
and -7 interact with K5, while the same amino acids of claudin-1 bind K12. The N/Q156 amino acid
of ECL2 of all three claudins interacts with lysine: in the case of claudin-1 this is L17 of PN159, for
claudin-4 L2, and for claudin-7 L6, L8, L15, L17. Based on the docking results, lysine, especially K1
and K5 and leucine L6 and L17 of PN159 interact with all three claudins examined (Figure 6D). After
docking of the peptide disappearance of β-strands in ECLs of claudins was observed (Figure 6B),
which seems to be correlated with the strength of interaction (Table 3). Comparing the docking energy
values of PN159 to claudins the following rank order in the strength of interaction can be established:
claudin-3 < claudin-1 < claudin-4< claudin-7. The energy values from modeling are shown in Table 3.
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3.7. Cell-Penetrating Effect and Uptake of PN159 Peptide in Epithelial Cells 
Besides the junctional effects, changes in the cell membrane integrity were also examined by 
ethidium homodimer-1 (856.77 Da) staining of Caco-2 epithelial cells after 24-h treatments in the 
concentration range of 1 to 10 μM. Only the highest PN159 concentration caused plasma membrane 
entry of the red fluorescent dye, which stained cell nuclei (Figure 7A). 
Figure 6. (A) Modeling human claudin-1, -4, -7 proteins. (B) Docking of PN159 peptide to claudin
proteins. Interacting residues are shown as sticks. Orange color: PN159 peptide; Yellow color: β-strands;
purple color: α-helices of claudins. (C) Amino acid sequence of ECL1 and ECL2 of human claudin
monomers 1, 4 and 7. Conserved amino acids are indicated in the boxes. The amino acids which
interact with PN159 according to docking studies are marked by yellow and light blue. Blue color
indicates interaction between the amino acids of claudins and PN159 peptide at the same position in
all three claudins. ECL: extracellular loop. (D) Interaction between PN159 peptide and human claudin
monomers 1, 4 and 7. Amino acids of PN159 peptide which interact with the claudins according
to docking.
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3.7. Cell-Penetrating Effect and Uptake of PN159 Peptide in Epithelial Cells
Besides the junctional effects, changes in the cell membrane integrity were also examined by
ethidium homodimer-1 (856.77 Da) staining of Caco-2 epithelial cells after 24-h treatments in the
concentration range of 1 to 10 µM. Only the highest PN159 concentration caused plasma membrane
entry of the red fluorescent dye, which stained cell nuclei (Figure 7A).Pharmaceutics 2019, 11, x FOR PEER REVIEW 14 of 21 
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The uptake of the fluorescently labeled PN159 peptide, reflected by the green fluorescent signal, 
was visualized by confocal microscopy (Figure 7B). In Caco-2 cells treated with 1 and 3 μM 
concentrations, the peptide was detectable in the cytoplasm as green dots. The cellular uptake of the 
peptide in cells incubated with 10 μM concentration was more pronounced. 
We confirmed the interaction of PN159 peptide with claudin-4 junctional protein by a co-
localization analysis. The labeled peptide was visible in the cytoplasm and also in the cell membrane 
at the level of intercellular junctions immunolabeled for claudin-4 (Figure 8). 
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3.8. Antimicrobial Effect of PN159 
We tested the antimicrobial activity of PN159 peptide on six ESKAPE pathogens (Table 4) at a 
wide range of concentration (0.8 to 70 μM). Among the tested bacteria Acinetobacter baumannii and 
Enterococcus faecium were the two most sensitive strains with MIC values below 5 μM. The 
concentration of PN159 to inhibit the growth of Staphylococcus aureus and Klebsiella pneumoniae was 
Figure 7. (A) Fluorescent staining of juntional protein zonula occludens-1 and double staining of
cell nuclei in Caco-2 cells after 1-h treatment with PN159 peptide. Green color: immun staining
for ZO-1. Red color: staining by ethidium h modimer-1 (EH-1), indicating increased membrane
permeability.Blue col r: staining of al cel n l . Bar = 10 µm. (B) Confocal microscopy
images of liv ng Caco-2 epithelial cel s inc ipy FL labeled PN159 peptide in different
concentrations for 5 min at 37◦C. Gre n color: - 159 peptide. Blue c lor: sta ing of cell
nuclei. Bar = 10 µm.
The uptake of fluorescently labeled PN159 peptide, r flected by the green fluorescent
sign l, was v sualized by confocal microscopy (Figure 7B). In Caco-2 cells reated with 1 and 3 µM
concentrations, the peptide was detectable i t c t l s as green dots. The cellular uptake of the
peptide in cells incubated with 10 µM concentration as ore pronounced.
We confirmed the interaction of PN159 peptide with claudin-4 junctional protein by a
co-localization analysis. The labeled peptide was visible in the cytoplasm and also in the cell membrane
at the level of intercellular junctions immunolabeled for claudin-4 (Figure 8).
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concentration of PN159 to inhibit the growth of Staphylococcus aureus and Klebsiella pneumoniae was 
Figure 8. Caco-2 cells were treated with Bodipy FL labeled P 159 peptide (5 min), then fluorescent
im unostaining of junctional protein claudin-4 and staining of cell nuclei were performed. Red color:
im unostaini g for claudin-4. Green color: i l ele P 159 peptide. Blue c lor: stai ing of
cell nuclei by H33342. Bar = 10 µm. rro i i te co-localization of claudin-4 and the labeled
PN159 pe tide.
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3.8. Antimicrobial Effect of PN159
We tested the antimicrobial activity of PN159 peptide on six ESKAPE pathogens (Table 4) at a
wide range of concentration (0.8 to 70 µM). Among the tested bacteria Acinetobacter baumannii and
Enterococcus faecium were the two most sensitive strains with MIC values below 5 µM. The concentration
of PN159 to inhibit the growth of Staphylococcus aureus and Klebsiella pneumoniae was around 10 µM,
which was in similar range where peptide effects were seen on human epithelial cells. The peptide
was still effective on the vancomycin-resistant Enterobacter cloacae and on Pseudomonas aeruginosa, but
at 10-times higher concentrations than in the case of the most sensitive pathogens.
As compared to the reference bactericidal antibiotic cefoxitin, PN159 was more effective in the
case of Acinetobacter baumannii, Enterococcus faecium, Enterobacter cloacae and Pseudomonas aeruginosa.
Gentamicin and ciprofloxacin showed strong antimicrobial activity for all ESKAPE pathogens, except
Enterococcus faecium. This strain was resistant for all investigated antibiotics, however, PN159 efficiently
inhibited its growth (Table 4).
Table 4. Antibacterial activity of PN159 peptide, cefoxitin, gentamicin and ciprofloxacin antibiotics on
ESKAPE pathogens. ATCC numbers are added in brackets. MIC (µM), minimal inhibitory concentration.
ESKAPE Pethogens (ATCC) PN159 Cefoxitin Gentamicin Ciprofloxacin
Acinetobacter baumannii (17978) 3.6 222.6 0.6 0.94
Enterococcus faecium (700221) 4.4 >222.6 >143.9 >30.18
Staphylococcus aureus (29213) 9.2 6.9 1.1 1.89
Klebsiella pneumonia (10031) 13.8 3.5 0.6 0.06
Enterobacter cloacae (13047) 31.0 >222.6 1.1 0.06
Pseudomonas aeruginosa (27853) 46.4 >222.6 2.3 1.89
3.9. The Effect of Cell-Penetrating Peptides on Intestinal Barrier Integrity
The kinetics of the effects of three other CPPs on Caco-2 cells were followed by real-time
impedance measurements (Figure 9A). The R8 and ϕ-peptides decreased the cell impedance during
the 24-h monitoring which indicates a cell reaction. Changes in cell index without cytotoxic effects
most probably are caused by an increase in plasma membrane ionic permeability. There was no major
influence of CPPs on barrier integrity (Figure 9B,C) as compared to the effect of PN159. We observed a
slightly decreased TEER in the case of R8 and ϕ-peptide and only the ϕ-peptide caused an elevated
permeability for the fluorescein marker molecule. Based on these results the investigated CPPs have
no significant opening effect on the intercellular junctions, which was also verified by immunostaining
for junctional proteins (Figure 9D).
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4. Discussion
We investigated for the first ti e the dual, TJ odulator and cell membrane actions of the PN159
peptide. PN159 was described as a TJ modulator and permeability-enhancing peptide on airway
epithelial cell layers in vitro and in vivo [4], and in our previous comparative work we found it also
very effective on culture models of the blood–brain and intestinal barriers [8]. The same peptide,
known also as KLAL or MAP was extensively studied for its cell membrane action as a CPP [10–12,35].
However, the identity of the differently named molecule was not previously known for the researchers
of the two fields. We demonstrated, that beside the cell-penetrating and antimicrobial effects, PN159 is
a TJ modulator on intestinal epithelial cells and by molecular modeling new members of the claudin
family were identified as its potential targets.
4.1. TJ Modulator Effect of PN159: Safety, Concentration Dependence and Reversibility
All the presented functional and morphological results point to the safe, concentration-dependent
and reversible TJ opening effect of PN159 in Caco-2 cells. The effect of the peptide on epithelial
cell viability was investigated for one and 24 h. We found that the peptide has no effect on cell
metabolism measured by MTT test or on impedance kinetics and can be considered as safe up to 10 µM.
The cha ges seen after higher, 30 µM concentration were fully reversible. The 100 µM concentration of
PN159 caused irreversible changes in both parameters on intestinal pithelial cells aft r either 1-h or
one-day treatment. Using respiratory epithelial issue (EpiAirway model) and MTT assay, PN159 was
found to b safe at concentrations up o 100 µM for a 1-h treatment [9]. The difference between the
sensi ivity of th epithelial mode s and also the sensitivity of the applied methods may explain the
dissimilarity of these data.
We found a marked concentration-dependence of the TJ modulator effect. With the most sensitive
method, TEER, we could determine that 1 µM PN159 already opened the paracellular cleft for ions,
while higher concentrations gradually decreased TEER. This TJ modulation by the effective but safe
10 µM concentration of the peptide was fast, within minutes, but after removal of the peptide a full
recovery was seen. This opening and complete recovery of the intestinal TJ structure was verified by
electron microscopy in the present study and by immunohistochemistry for TJ proteins both in this
and our previous work [8]. A similar concentration-dependent and reversible effect of PN159 on TEER
was found on airway epithelial tissue, too [4].
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The concentration dependence of the TJ modulator effect of the peptide was also detected in the
permeability assay for a small and a large hydrophilic marker, fluorescein and albumin. A similarly
high permeability increase with a full reversibility was measured for the same markers on both Caco-2
and blood–brain barrier culture models with the 10 µM concentration of PN159 peptide [8]. This action
of the peptide was verified by the immunostaining of junctional proteins with higher concentrations
causing bigger alterations in junctional protein intensity and distribution. Other claudin-specific TJ
modulator peptides act similarly on junctional protein staining as well as on permeability of epithelial
and endothelial cells [36,37].
In addition, the opening of the paracellular pathway in Caco-2 monolayers was measured by four
dextran markers with size between 4 and 40 kDa. The apparent permeability coefficients of the large
dextran macromolecules were very low in control conditions. PN159 treatment (10 µM) elevated the
dextran penetration by 159- to 400-fold. The highest increase was measured in the case of the largest,
FD-40 marker. The concentration dependency of the permeability increasing effect of PN159 was also
observed on the EpiAirway model, but in the concentration range of 25 to 100 µM. The elevation of the
permeability was 10- to 30-fold for FD-4 [4] and for peptide hormones with the same size [9].
To study the effect of PN159 on drug penetration, we tested two hydrophilic and two lipophilic
drugs, which are substrates of active efflux transporters [24,38]. The permeability of hydrophilic
atenolol and cimetidine was very low, while high penetration was measured for the lipophilic quinidine
and verapamil on Caco-2 cells in agreement with our previous study [24]. PN159 treatment caused
more than 30-fold permeability elevation for atenolol and cimetidine which penetrate slowly across
the cell’s layers. The peptide increased about 2-fold the permeability of the intestinal culture model for
the lipophilic quinidine and verapamil, which already showed a high penetration. The permeability
of the slightly lipophilic plant alkaloid, galantamine (287 Da), a substrate of P-glycoprotein, was
also increased 2 to 3-fold by PN159 in airway epithelial tissue model [9] confirming the peptide’s
penetration enhancer effect.
4.2. Tight Junction (TJ)Modulator Effect of PN159: Interaction with Claudins
In our previous study, binding of PN159 in the micromolar range to epithelial claudin-1
and endothelial claudin-5 was demonstrated by affinity measurements and confirmed by docking
studies [8]. In this report we describe an additional two intestinal epithelial junctional proteins,
claudin-4 and -7 which are highly expressed in Caco-2 cells [34], as potential targets of the peptide
by molecular docking. All these results suggest that PN159 peptide may open cell–cell junctions by
acting on claudins, the most prominent family of integral membrane junctional proteins. C-CPE and
C1C2 tight junction modulator peptides were also described to target claudins. C-CPE is a fragment
of Clostridium perfringens enterotoxin which directly binds claudin subtypes including claudin-3 and
-4 and induces disintegration of tight junctions [39]. The peptidomimetic C1C2 which contains the
C-terminal half of ECL1 of claudin-1 predominantly binds to claudin-1 and -5, opens the paracellular
barrier in cultured cells and causes cytosolic distribution of claudin-1, -2, -3, -4, and -5 [36]. What is
common in the action of these three TJ modulator peptides is that they have specific interactions with
conserved amino acids of claudins [8,40], however, these peptides do not share any similarity in their
amino acid sequence. The secondary structure of C1C2 consists of β-sheet stabilized by α-helix [40],
the claudin-binding domain of C-CPE is a nine-stranded β-sandwich [41], while according to our
CD measurements and molecular modelling PN159 also contains β-sheet in addition to α-helix. This
structural similarity between the three different but claudin-targeting peptides may be linked to the TJ
modulator effect.
4.3. Cell Penetration and Antimicrobial Effect of PN159
We observed a concentration-dependent cellular uptake of PN159 on intestinal barrier cells as
reflected in the confocal microscope images. PN159 has a fast uptake in human melanoma cells,
treatment with 1 µM concentration already causing detectable entry of the peptide into the cells, in
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concordance with our results [12]. The cellular uptake of PN159 was also verified on other four cell
lines [42]. After treatment with a concentration of 10 µM, the peptide entered the cytoplasm of cells
without cytotoxic effects, similar to our data.
Most of the CPPs have antimicrobial activity due to their structural properties, especially the
cationic and the amphipathic membrane active peptides [13]. Based on literature data the amphipathic
PN159 effectively inhibited the growth of different microorganisms, like Escherichia coli, Staphylococcus
epidermidis, Bacillus megaterium, Saccharomyces cerevisiae [10,19,43]. In this study we demonstrated
the antimicrobial activity of PN159 peptide in the concentration range of 3–46 µM on clinically
relevant ESKAPE pathogens. As compared to the reference antibiotics, PN159 was more effective in
the inhibition of the growth of Acinetobacter baumannii, Enterococcus faecium, Enterobacter cloacae and
Pseudomonas aeruginosa. (Table 4).
Comparing our results with data from the literature, another amphipathic antimicrobial peptide,
melittin, inhibited the growth of Escherichia coli and Micrococcus luteus [44] and was also tested against
three of the ESKAPE pathogens. Acinetobacter baumannii and Pseudomonas aeruginosa were more
sensitive for melittin treatment, than Klebsiella pneumoniae: for the inhibition of growth of Klebsiella
pneumoniae more than 100 µM melittin was needed [45], while in our study around 10 µM PN159 was
already effective.
PN159, as a model amphipathic CPP peptide, strongly interacts with biological membranes due to
its physical-chemical properties. As a CPP, PN159 enters epithelial cells [42], enhances the membrane
penetration of molecules and exerts antimicrobial effects [10,11]. Because PN159 binds different
claudins and interacts specifically with their conserved amino acids, it acts as a TJ modulator [8].
It is an open question, however, if the plasma membrane and the TJ modulator actions of PN159 are
connected or not.
4.4. TJ Modulator Effect of Other CPPs?
Based on these results we asked the question whether this TJ modulator ability is a unique
effect of PN159 among the CPPs or not. Therefore, we have tested two other amphipathic CPPs,
the widely used Pep-1 [16] and the cyclic ϕ-peptide [15], and one cationic CPP, R8 peptide [18]
on the barrier integrity of Caco-2 monolayers. None of the tested CPPs had a TJ modulator effect
similar to PN159. There was no change in the TEER values and only the ϕ-peptide increased the
permeability of fluorescein. Since no effect was seen on junctional staining in epithelial cells treated
with ϕ-peptide, the increase in permeability and decrease in the cell layer impedance may be linked
to the cell membrane action of this CPP [15]. As we demonstrated by our modeling results, PN159
peptide interacts with conserved residues of the claudins investigated (Figure 6) suggesting its ability
for specific interactions [8]. The amino acid sequence of PN159 results in an amphipathic helix
structure [10], which is not characteristic of the other CPPs investigated in our paper. From the other
three investigated peptides, R8 and ϕ-peptide have positively charged arginine clusters (Table 1) and
are considered as clearly cationic CPPs [17]. Pep-1 also contains a positively charged amino acid cluster
and is rich in tryptophan repeats (Table 1). Neither PN159 contains clusters of arginine or positively
charged amino acids, nor tryptophan (Table 1). While we have not found a CPP with a TJ modulator
effect in the current study, we cannot exclude that other membrane active peptides can have such dual
action. The amphipathic antimicrobial peptide melittin enhanced the paracellular permeability for
dextran marker molecules on Caco-2 cells [46]. The opening of TJs by melittin was mediated, at least
partially, by the prostaglandin signaling pathway [46].
5. Conclusions
We demonstrated that PN159 (KLAL/MAP) peptide as a penetration enhancer has a dual
action on intestinal epithelial cells. The peptide safely and reversibly enhances the permeability
of model molecules and drugs through intestinal epithelial cell layers by opening the intercellular
junctions. We identified claudin-4 and -7 junctional proteins by docking studies as potential binding
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partners and targets of the peptide in the opening of the paracellular pathway. In addition to the
tight junction modulator action, the peptide has a concentration-dependent cellular uptake and
cell membrane permeabilizing effect, which can also contribute to its penetration-enhancing effect.
This dual action is not general for cell-penetrating peptides, since the other three CPPs tested did not
show barrier opening effects. Therefore, we propose the investigation of CPPs for testing their effect
on paracellular permeability.
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